Last reviewed · How we verify

Remifentanil, propofol and citanest

University of Aarhus · FDA-approved active Small molecule

Remifentanil, propofol and citanest is a General anesthetic combination Small molecule drug developed by University of Aarhus. It is currently FDA-approved for Induction and maintenance of general anesthesia for surgical procedures.

This is a combination of three anesthetic agents that work synergistically to induce and maintain general anesthesia through different mechanisms.

This is a combination of three anesthetic agents that work synergistically to induce and maintain general anesthesia through different mechanisms. Used for Induction and maintenance of general anesthesia for surgical procedures.

At a glance

Generic nameRemifentanil, propofol and citanest
SponsorUniversity of Aarhus
Drug classGeneral anesthetic combination
TargetMu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Remifentanil is an opioid agonist that provides analgesia and sedation by binding to mu opioid receptors. Propofol is a sedative-hypnotic that enhances GABA-mediated inhibition in the central nervous system. Prilocaine (citanest) is a local anesthetic that blocks sodium channels in nerve membranes. Together, they provide rapid induction and maintenance of general anesthesia with analgesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Remifentanil, propofol and citanest

What is Remifentanil, propofol and citanest?

Remifentanil, propofol and citanest is a General anesthetic combination drug developed by University of Aarhus, indicated for Induction and maintenance of general anesthesia for surgical procedures.

How does Remifentanil, propofol and citanest work?

This is a combination of three anesthetic agents that work synergistically to induce and maintain general anesthesia through different mechanisms.

What is Remifentanil, propofol and citanest used for?

Remifentanil, propofol and citanest is indicated for Induction and maintenance of general anesthesia for surgical procedures.

Who makes Remifentanil, propofol and citanest?

Remifentanil, propofol and citanest is developed and marketed by University of Aarhus (see full University of Aarhus pipeline at /company/university-of-aarhus).

What drug class is Remifentanil, propofol and citanest in?

Remifentanil, propofol and citanest belongs to the General anesthetic combination class. See all General anesthetic combination drugs at /class/general-anesthetic-combination.

What development phase is Remifentanil, propofol and citanest in?

Remifentanil, propofol and citanest is FDA-approved (marketed).

What are the side effects of Remifentanil, propofol and citanest?

Common side effects of Remifentanil, propofol and citanest include Respiratory depression, Hypotension, Bradycardia, Nausea and vomiting, Injection site pain.

What does Remifentanil, propofol and citanest target?

Remifentanil, propofol and citanest targets Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine) and is a General anesthetic combination.

Related